bluebird bio (BLUE) Bullish View Reiterate at Post Q3 and Ahead of ASH Abstract Data -Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.Lam ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
